Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 1 Components of outbreak investigations after detection of CRPA stratified by endemic and epidemic setting as well as low and high prevalence for CRPA in European countries

From: Outbreak investigations after identifying carbapenem-resistant Pseudomonas aeruginosa: a systematic review

 

Endemic setting (N = 45)

Epidemic setting (N = 81)

P value

Low prevalence countries (N = 44)1

High prevalence countries (N = 8)2

P value

Median number of components (range)

2 (1–5)

2 (1–5)

0.697

2 (1–5)

1.5 (1–4)

0.833

Components of outbreak investigations

1) Identifying contact patients (%)

4 (8.9)

18 (22.2)

0.059

9 (20.5)

2 (25.0)

–

2) Screening of contact patients (%)

3 (6.7)

16 (19.8)

0.043

8 (18.2)

2 (25.0)

–

3) Screening on admission (%)

21 (46.7)

13 (16.0)

 < 0.001

15 (34.1)

1 (12.5)

–

4) Screening during hospitalization (%)

21 (46.7)

30 (37.0)

0.291

18 (40.9)

4 (50.0)

–

5) Screening of HCW (%)

12 (26.7)

25 (30.9)

0.620

13 (29.5)

0 (0)

–

6) Screening of the environment (%)

 Dry environment (%)

 Wet environment (%)

28 (62.2)3

15 (33.3)4

25 (55.6)7

72 (88.9)

38 (46.9)5

68 (84.0)6

 < 0.001

0.292

0.002

33 (75.0)

16 (36.4)7

31 (70.5)8

7 (87.5)

3 (37.5)

7 (87.5)6

–

–

–

7) Other (%)

5 (11.1)

2 (2.5)

–

1 (2.3)

0 (0)

–

  1. CRPA carbapenem-resistant Pseudomonas aeruginosa. HCW healthcare worker. Bold font indicates significant difference. –expected count lower than five, therefore, no P value was calculated
  2. 1Low prevalence was defined as < 10%, CRPA according to the EARS-Net [22]. Data on prevalence was only available for European countries
  3. 2high prevalence was defined as ≥ 10%, CRPA according to the EARS-Net [22], Data on prevalence was only available for European countries
  4. 3Information from one study missing
  5. 4information from five studies missing
  6. 5information from seven studies missing
  7. 6information from three studies missing
  8. 7information from four studies missing
  9. 8information from two studies missing
Back to article page

Antimicrobial Resistance & Infection Control

ISSN: 2047-2994

Contact us